Form D · Biotechnology
MatriTek, Inc.
New York, NY · CIK 0001671106
Offering snapshot reported Apr 15, 2016 · SEC filing
- Reported sold
- $1.1M Offering amount: $1.5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 31, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 15, 2016 | Initial | $1,100,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-261458
Source: Form D, filed Apr 15, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Bacchetta | Director |
| David Elmaleh | Director |
| Ljiljana Kundakovic | Executive |
| Gordana Vunjak Novakovic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2700 Broadway Apartment 4 G
New York, NY, 10025
New York, NY, 10025